All News

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and updated data presented at conferences.

AI revolutionizes pharmacy by automating workloads, enhancing patient care, and navigating drug pricing challenges amid evolving federal policies.

These pieces highlight several newly approved therapies that expanded treatment options across multiple disease states.

From home-based monitoring and subcutaneous immunotherapy to expanded community cancer networks, 2025 marked a pivotal year in rethinking how cancer care is delivered.

New treatments, care gaps, and cardiac monitoring were major focuses in cardiovascular news this year.

New research highlights the effectiveness of RSV preF vaccines in preventing severe respiratory infections in older adults.

Highlights from the 2025 Muscular Dystrophy Association (MDA) Conference include clinical updates, expert insights, and breaking trial findings.

Our top 5 obesity articles of 2025 highlight GLP-1 prescribing trends, insurance coverage, co-pay caps, real-world use, and access challenges.

Acute exacerbations of chronic rhinosinusitis are poorly defined and often overtreated, calling for standardized diagnostic criteria and more evidence-based management.

The most-read articles focused on soft tissue sarcoma research, including innovative biomarkers, treatment strategies, and multidisciplinary care challenges.

New therapies and individualized care plans for menopausal women highlighted the most-read 2025 SABCS coverage.

These are the most popular multiple myeloma articles from 2025.

Explore the evolving landscape of drug pricing, reproductive rights, and health policy in 2025, featuring insights on SC pembrolizumab and RFK Jr's hearings.

Exercise enhances quality of life and sleep for those with ovarian cancer, highlighting the need for further research in supportive care.

The 2025 Community Oncology Conference, hosted by COA, reflected a commitment to patient-centered care, access, and innovation in community oncology.

The most-viewed content focused on the “One Big Beautiful Bill,” the Most Favored Nation drug policy, and other changes under the Trump administration.

Our top dermatology content of 2025 highlights AI wearables, new biologics, emerging vitiligo treatments, and strategies for rare and complex skin diseases.

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

From cutting-edge AI detection tools to rising incidence in younger adults and threats to free screenings, 2025 brought major shifts in the struggle against colorectal cancer.

The top ophthalmology content included FDA approvals, FDA complete response letters, and new associations between cataracts and antioxidant index.

Alopecia areata significantly impacts quality of life, driven by appearance-related anxiety related to where hair loss occurs more than how much is lost.

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable toxicity in older, chemotherapy-ineligible patients with LBCL.

Explore the top 5 insights on managed care, public health policy, and emerging health trends shaping 2025's health care landscape.

This year’s most-read articles on CLL highlighted research and insights on personalized therapy, long-term remission, and next-generation cell treatments.

Highlights from EHA 2025 included use of bispecific antibodies in more settings and novel approaches for improving outcomes in hard-to-treat patients.

Sequential BTK and BCL2 inhibitors yield high initial response rates, but durability remains a challenge in the real-world setting for CLL.